Evidence map›Paper›PMID 30197040›Full record

Trial reportEuropean urology focus2018

Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naïve High-grade Non-muscle-invasive Bladder Cancer.

Robert S Svatek, Cathy Tangen, Scott Delacroix, William Lowrance, Seth P Lerner

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European urology focus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  7. Review
  8. Emerging molecular therapies in the treatment of bladder cancer.Exploration of targeted anti-tumor therapy · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Robert S SvatekDepartment of Urology, University of Texas Health San Antonio, San Antonio, TX, USA. Electronic address: svatek@uthscsa.edu.
Cathy TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Scott DelacroixLouisiana State University, Department of Urology and Gulf South NCORP, New Orleans, LA, USA.
William LowranceDepartment of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Seth P LernerScott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Baylor College of Medicine · USFred Hutch Cancer Center · USHuntsman Cancer Institute · USLouisiana State University · USThe University of Texas Health Science Center at San Antonio · US

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888
6 · The paper itself

Abstract

The S1602 Intergroup trial is a randomized phase III clinical trial that aims to test two important hypotheses: (1) priming with intradermal bacillus Calmette-Guérin (BCG) vaccine prior to standard intravesical BCG improves response to BCG in terms of recurrence-free survival and (2) Tokyo-172 BCG strain is non-inferior to TICE BCG in terms of time to high-grade recurrence. The study was approved by the Cancer Therapy Evaluation Program of the National Cancer Institute and activated in spring 2017. Here, we provide a synopsis of the study background, design, and update of the clinical trial.

Indexed as

BCG VaccineUrinary Bladder NeoplasmsAdjuvants, ImmunologicFemaleHumansImmunity, CellularImmunotherapyInjections, IntradermalMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingProgression-Free SurvivalT-LymphocytesTreatment OutcomeAdjuvants, ImmunologicBCG Vaccine

Identifiers

PMID30197040
PMCPMC6581029
OpenAlexW2890377175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.